It is tempting to speculate that STAT3 activation is involved in DNM2 upregulation in cancers and that DNM2 overexpression may be an effector of features associated with abnormal STAT3 activation in cancers such as tumor growth and metastasis leading to poor prognosis [49–51]. This evidence concerns the gene DNM2 and cancer.